Prevalence and functional consequence of PHOX2B mutations in neuroblastomaEric H. Raabe, John M. Maris, Mark L. Laudenslager et al.|Oncogene|2007Cited by 154
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Louis Chesler et al.|Nature Medicine|2023Cited by 125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Yaël P. Mossé et al.|Clinical Cancer Research|2018Cited by 88
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersAdam J. Wolpaw, Yaël P. Mossé, Richard Bayliss et al.|Cancer Research|2021Cited by 70
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastomaRenata Sano, Yaël P. Mossé|Science Translational Medicine|2019Cited by 68